Calls to pull newly approved RSV shots from market intensify amid deaths and injuries

(NaturalHealth365)  RSV, or Respiratory Syncytial Virus, has been known since the mid-1950s.  It’s long been understood to primarily impact vulnerable demographics like infants, young children, older adults, and those with weakened immune systems.  Unsurprisingly, pharmaceutical giants have seized upon this health concern as a lucrative opportunity, developing shots aimed at mitigating or preventing RSV-related complications.

Yet, amidst the push for RSV jabs, skepticism looms large.  Health industry watchdogs and public health advocates are raising red flags about the recently approved shots.  According to reports from the Vaccine Adverse Event Reporting System (VAERS), a national surveillance program for monitoring vaccine safety, there have been 302 instances of serious side effects linked to RSV jabs as of February 23, 2024.

Is it time to pull RSV jabs from the market?

Aside from the 302 serious injuries noted by VAERS, the jabs also led to (at least) four reported deaths.  Alarmingly, a significant portion of these adverse reactions occurred among individuals aged 60 and above.

Adding to the distress, RSV injections have also been linked to cases of Guillain-Barre syndrome, a rapid onset of muscle weakness caused by the immune system attacking the body’s peripheral nervous system.  As of the time of writing, there have been 34 reported cases of Guillain-Barre syndrome associated with the RSV injection.

Guillain-Barre syndrome can lead to a range of serious health complications, including respiratory issues, pressure ulcers, blood clots, bladder dysfunction, severe pain, elevated blood pressure, heart problems, and persistent numbness.

What’s particularly concerning is that RSV injections are still in their infancy, yet they’re already proving to be overwhelmingly detrimental to human health.  Despite mounting evidence of safety concerns, the FDA continues to downplay the risks associated with Guillain-Barre syndrome after RSV injection.  It’s abundantly clear that this so-called “health” agency is prioritizing the interests of Big Pharma over public safety, perpetuating a dangerous cycle of influence and complacency.

Unapproved use of RSV shots across age groups raises concerns

The U.S. Food and Drug Administration (FDA) approved Pfizer’s Abrysvo and GSK’s Arexvy RSV shots for adults aged 60 and above, specifically excluding children and infants.  Believe this or not, Abrysvo is also cleared for pregnant women.  However, it’s troubling to discover that some newborns experienced severe effects, including the tragic death of an infant less than a month old, due to incorrect shot administration.

Despite these concerning incidents, nearly 10 million doses of both companies’ RSV shots were administered as of last month.  Shockingly, during the initial 10-month rollout alone, there were 34 fatalities.  One might expect such tragedies to prompt the removal of RSV jabs from the market.  However, they remain readily available to anyone interested.

Arm your body against pathogenic invaders by improving your immune system

Medalerts.org
Childrenshealthdefense.org
Mayoclinic.org

The post Calls to pull newly approved RSV shots from market intensify amid deaths and injuries appeared first on NaturalHealth365.

Visit Natural Health 365 Here /